Pharm Cardiology Exam 2 Flashcards

(129 cards)

1
Q

Weight loss lowers SBP in HTN by

A

5 mmhg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Healthy Diet lowers SBP in HTN by

A

11 mmhg

DASH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Reduced sodium lowers SBP in HTN by

A

5/6 mmhg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Aerobic physical activity lowers SBP in HTN by

A

5/8 mmhg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Lowering alcohol intake lowers SBP in HTN by

A

4 mmhg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

1st line HTN Meds

A
ABCD
ACE/ARB
Beta Blocker (only if HFrEF, MI or CAD)
CCB (dipines) (amlodipine)
Diuretics (low dose HCTZ)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Angiotensinogen pathway

RAAS

A
Liver makes angiotensinogen
Kidney makes Renin
Renin makes angiotensin I
Lungs make ACE
Ace makes Angiotensin II
Angiotensin II Receptor
Vessels, Heart, Kidneys, CNS

Renin inhibitor,
ACE inhibitor,
Angiotensin II receptor blocker (ARB)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Amlodipine

A

Norvasc (CCB)
HTN
5mg QD

Contra:
Obstructive coronary disease, aortic stenosis, CHF

Interactions
May be potentiated by CYP3A inhibitors

Adverse:
Edema, Fatigue, drowsiness, palpitations, dizzy, nausea, flushing, abdominal pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

HCTZ

A

HTN (thiazide diuretic)
25mg QD

Contra:
Anuria, sulfa allergy

Warning:
Renal/hepatic impairment, arrhythmia, DM, Gout

Interactions
Digitalis, Lithium toxicity

Adverse
Electrolyte imbalance, hypokalemia, hyperkalemia, hyperuricemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

HCTZ vs Chlorthalidone

A

HCTZ has shorter half life

10-12 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Alpha 1 blockers

A

Associated with orthostatic hypotension
-zosin
Used in BPH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Alpha 2 agonists

A

stimulates alpha 2 in brain
decreases CO and PVR
Clonidine, methyldopa

Should be last line due side effects, cant discontinue suddenly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Clonidine

A
Sympatholytic
Alpha 2 agonist
for 
HTN, 
ADHD, 
anxiety, 
Withdrawal, 
migraine, 
menopausal flushing, 
diarrhea
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Methyldopa

A

Pro drug used as sympathoplegic
Alpha 2 agonist

Gestational HTN

Significant side effects are
Rebound HTN
depression
Sexual dysfunction
Memory impairment
tolerance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Direct acting vasodilators

A

Hydralazine
Sodium Nitroprusside

associated with sodium and water retention

Need to be used with diuretic and BB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Aliskiren

A

Direct renin inhibitor
HTN

Contraindications
ACE/ARB in diabetics

Warning
Fetal Toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Indications for Systolic heart failure

A

ACE/ARB
BB
Diuretic
Aldosterone ag

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Indications for Post MI

A

ACE
BB
ARB
Aldosterone ag

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Indications for proteinuric CKD

A

ACE/ARB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Indications for Angina

A

BB,

CCB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Indications for A fib Rate control

A

BB,

CCB (Diltiazem/verapamil)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Indications for A flutter rate control

A

BB,

CCB (Diltiazem/verapamil)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Contraindications for Angioedema

A

ACE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Contraindications for Bronchospastic disease

A

BB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Contraindications for Depression
Reserpine
26
Contraindications for Liver disease
Methyldopa
27
Contraindications for Preganancy
ACE ARB Renin inhib
28
Contraindications for 2nd/3rd AV block
BB, | CCB (Diltiazem/verapamil)
29
Mean arterial pressure (MAP) reduction in HTN emergencies
Should be reduced by 10 - 20 percent in first hour then gradually during next 23 hours to a total of 25% of baseline Otherwise can worsen organ ischemia
30
Common cause of HTN Emergency
``` Drugs that produce hyperadrenergic state Cocaine amphetamine PCP MAOI recent discontinuation of clonidine ```
31
Meds to use in HTN emrgencies
Sodium nitroprusside or nitro CCB (clevidipne) (ultra short acting) (nicardipine) Dopamine agonist - fenoldopam BB - labetalol, esmolol, metoprolol
32
Nitroprusside indications
Vasodilator HTN emergency Caution with High ICP or azotemia
33
Nicardipine indications
CCB HTN emergency Not with acute heart failure Caution with coronary ischemia
34
Nitro indications
Vasodilator | Coronary ischemia
35
Fenoldopam indications
Dopamine 1 agonist HTN emergency Caution with glaucoma
36
Hydralazine indications
Direct vasodilator | eclampsia
37
Fenoldopam
Dopamine Receptor agonist Peripheral arteriolar dilator for HTN Emergencies For the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function. Children: for the in-hospital, short-term (up to 4 hours) reduction in blood pressure. Avoid in patients with glaucoma (Increased IOP) Interactions: Avoid with BB given with continuous IV infusion Adverse Reflex tachycardia, HA, Flushing
38
HTN in black patients
Monotherapy = CCB or thiazide Dual therapy = CCB + ACE/ARB If patient has edema or hypervolemia ACE/ARB +Thiazide If CCB+ Ace/ARB not working, add thiazide next add spironolactone / eplerenone
39
HTN in pregnancy | Contraindicated Meds
ACE ARB direct renin inhibitors
40
HTN in pregnancy
For acute HTN lowering IV labetalol or hydralazine Treatment should begin when SBP >160 Classes
41
Labetalol class
Alpha and beta blocker
42
Hydralazine
Peripheral vasodilator
43
Nifedipine
CCB (dihydropyridine)
44
Methyldopa
Central acting alpha agonist
45
HTN in elderly
``` 1st line Thiazide CCB ACE ARB ``` CCB & Thiazide works best in elderly
46
Treatment for orthostatic HTN
Fludrocortisone Starting with low-dose fludrocortisone (0.1 mg/day) for patients with volume depletion and disabling symptoms despite nonpharmacologic measures. A sympathomimetic pressor agent, such as midodrine or droxidopa, can be added or substituted in patients who remain symptomatic on or cannot tolerate fludrocortisone.
47
Fludrocortisone
Corticosteroid 0.1 mg QD up to 0.3 mg QD Up titrate0.1mg every week as needed Max dose 1mg per day Taken with high salt diet and plenty of fluid Adverse Hypokalemia, ankle edema, CHF
48
Midodrine
Symptomatic orthostatic hypotension Alpha adrenergic agonist 10mg TID during daytime hours Staring does is 2.5mg Contra: Severe heart disease, acute renal disease, urinary retention, Pheochromocytoma, thyrotoxicosis, excessive supine hypertension Adverse Paresthesia, piloerection, dysuria, pruritis, supine hypertension
49
MOA midodrine
Rapidly absorbed after PO Metabolized in liver/ tissues Activates a1 receptor causing vasoconstriction increased SBP/DBP while standing, sitting, supine For postural hypotension after non pharm fails
50
Shock Tx
Vasopressors (alpha 1) Norepi, epi, phenylephrine, dopamine ADH Vasopressin: Pitressin, vasostrict Inotrope Beta 1: Dobutamine Inotrope PDE 3 inhib: Milrinone
51
Vasopressors
Alpha 1 adrenergic Norepi (levophed) Epi Phenylephrine Dopamine
52
Norepi
Levophed Sympathomimetic Contra: Hypotension due to blood volume deficits except in emergencies, mesenteric or peripheral vascular thrombosis Adverse: Ischemic injury, Reflex bradycardia, arrhythmias, anxiety
53
EPI
Increase MAP in hypotension with shock Sympathomimetic Adverse Anxiety, apprehensiveness, tremors, weakness, dizzy, sweating, palpitations
54
Phenylephrine
Hypotension resulting from vasodilation in the setting of anesthesia Sympathomimetic Adverse NV, HA, vasoconstriction, ischemia, severe bradycardia, renal toxicity
55
Dopamine
Dopamine receptor and beta 1 at low dose it constricts vessels other than in kidney and brain at high does it constricts all vessels increases cardiac contractility and increases SBP Used for shock related to under perfusion and reflex vasoconstriction Used in renal failure with shock
56
Vasopressin
Vasostrict Synthetic vasopressin contra Chlorobutanol allergy Adverse Decreased CO, bradycardia, tachyarrhythmias, hyponatremia, ischemia
57
Dobutamine
Dose = 2-20 mcg/kg/min (max 40) Receptors B1, B2, A1 Adverse Tachyarrhythmias, HTN, Hypotension, Nausea, HA
58
Milrinone
Reduces left ventricular filling pressure in chronic heart failure patients May be the preferred inotropic drug for patients receiving BB as it does not use the Beta receptor to drive cardiac contractility. (unlike dopamine and dobutamine) Through its enhancement of cAMP may reduce pulmonary artery pressure via a vasodilator mechanism and therefore may improve right heart failure due to pulmonary hypertension
59
Statins
``` Atorvastatin Fluvastatin Lovastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin ```
60
High intensity statins
Rosuvastatin 20-40mg Atorvastatin 40-80mg >50% LDL reduction Rosuvastatin, atorvastatin and simvastatin cause the greatest reduction in LDL
61
Atorvastatin
HMG-COA reductase inhibitor ``` Contraindications Active liver disease Unexplained elevated serum transaminases Pregnancy Nursing mothers ```
62
Bile acid sequestrants
Colesevelam binds with bile acids in the intestine to form an insoluble complex that is eliminated in feces. This increased excretion of bile acids results in an increased oxidation of cholesterol to bile acid and a lowering of the serum cholesterol.
63
colesevelam
Pregnancy cat B Contra Hx of bowel obstruction, Serum TGL over 500, Hx of hyperTGL induced pancreatitis Adverse Constipation, nausea, dyspepsia, dysphagia, pancreatitis
64
Fibrates
Fenofibrate, Gemfibrozil Adverse Liver function tests increased (dose related; 3% to 13%; ALT/AST increased >3 x ULN: 5% to 13%) Abdominal pain-5%; URI-6% Can lower serum TGL up to 50% and Raise serum HDL up to 20%
65
Fenofibrate
hypertriglyceridemia Fibrate Contra: Hepatic/renal dysfunction, primary biliary cirrhosis, gallbladder disease Adverse myopathy, abnormal LFT's, elevated CPK Warnings renal impairment, monitor CBC for 1 yr, monitor LFT's, discontinue if >3 x normal Interactions Avoid statins, potentiates oral coags
66
Ezetimibe
Zetia (10mg QD) Cholesterol absorption inhibitor Interaction Other fibrates except feonfibrate Contra with statin in active liver disease or unexplained elevations in serum transaminases Adverse Diarrhea 4%, Arthralgia 3%, URI 4%
67
Ezetimibe MOA
Cholesterol absorption inhibitors that impair dietary and biliary cholesterol absorption at the brush border of the intestine without affecting the absorption of triglycerides or fat soluble vitamin.
68
Statins in pregnancy
Statins are contraindicated in | pregnancy and nursing mothers
69
Lipid regulating agents
Omega 3 acid ethyl esters (Lovaza) Icosapent ethyl (vascepa)
70
Omega 3 acid ethyl esters
(Lovaza) Adjunct to diet to reduce very high TGL (>500) Lipid regulating agent Interaction May potentiate anti coagulants (monitor) Adverse Eructation, dyspepsia, rash, taste perversion, Increased ALT,AST,LDL
71
Icosapent ethyl
(vascepa) Lipid regulating agent Increased risk of bleeding with antithrombotics (ASA, Clopidogrel, warfarin etc.) Adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adults with elevated triglyceride (TG) levels (≥150mg/dL) and established cardiovascular disease (CVD), or diabetes plus ≥2 additional CVD risk factors. The effect of Vascepa on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
72
Nicotinic acid
Niacin Raises HDL up to 30-35% by reducing lipid transfer of cholesterol from HDL to VLDL and by delaying HDL clearance NO flush doesn't work Can use ASA 325mg 30 min / NSAID 200mg 60 min prior to reduce flush (reduce prostaglandin effect) Sustained release can lead to Hepatotoxicity
73
Niacin Adverse
Can increase glucose levels worsening uncontrolled DM Worst with Extended release tablets Can cause hyperuricemia and lead to gout can cause hypotension if on vasodilators and worsen unstable angina can cause bleeding in patients with bleeding issues
74
PCSK9 Inhibitor | Proprotein convertase subtilisin/kexin type 9
Can lower LDL by 60% in patient on statins Can reduce risk of CVA or MI Alirocumab (praluent), Evolocumab (reptha)
75
PCSK9 inhibitor MOA
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme produced in the liver. PCSK9 binds to the low density lipoprotein receptor on the surface of hepatocytes, leading to its degradation and higher plasma LDL-cholesterol (LDL-C) levels. Blocking PCSK9 with antibodies leads to lower plasma LDL-C levels.
76
Alirocumab
PCSK9 Inhibitor Warnings 2nd and 3rd trimester
77
Hypertriglyceridemia
All such patients should have LDL-C lowered with statin therapy if indicated. Statins typically lower TG levels by 5 to 15 percent; however, high-intensity statin therapy can lower TGs by 25 to 30 percent
78
Hypertriglyceridemia over 885
For patients with TG levels persistently >885 mg/dL (10 mmol/L) after nonpharmacologic interventions, we suggest starting drug therapy to lower the risk of pancreatitis. We start treatment with a fibrate, which may lower TGs by up to 70 percent . We choose fenofibrate rather than gemfibrozil due to the likelihood of either concurrent or later use of a statin. Gemfibrozil has a higher risk of muscle toxicity, especially when administered with many statins.
79
Hypertriglyceridemia between 150 and 885
if already taking statins add icosapent ethyl (vascepa)
80
Which of the below HTN medications is not contraindicated in pregnant patients? aliskiren (Tekturna) lisinopril (Zestril) valsartan (Diovan) methyldopa (Aldomet)
methyldopa (Aldomet)
81
Which electrolyte disorders is sometimes associated with HCTZ? Hypernatremia Hypokalemia Hyperkalemia Hyponatremia
Hypokalemia
82
Which is not considered a first-line parenteral medication for HTN emergencies? sodium nitroprusside (Nitropress) clonidine (Catapress) fenoldopam (Corlopam) labetalol (Trandate)
clonidine (Catapress)
83
What is the common dosage for the drug flurdrocortisone (Florinef) for the initial treatment of orthostatic hypotension? 0.1 mg-0.2 mg once a day 0.2 mg-0.4 mg once a day 0.4 mg-0.8 mg once a day 1-2 mg once a day
0.1 mg-0.2 mg once a day
84
Which of the below medications is not considered a vasopressors (alpha-1 adrenergic? norepinephrine (Levophed) dobutamine (Dobutrex) phenylephrine (Biorphen or Neo-Synephrine) dopamine (Inotropin)
dobutamine (Dobutrex)
85
Which of the vasopressors is generally used for patients with shock and renal failure? norepinephrine (Levophed) dobutamine (Dobutrex) phenylephrine (Biorphen or Neo-Synephrine) dopamine (Inotropin)
dopamine (Inotropin)
86
Which of the following medications is considered a medication for high-intensity statin therapy for HLP? pravastatin (Pravachol) rosuvastatin (Crestor) simvastatin (Zocor) lovastatin (Mevacor)
rosuvastatin (Crestor)
87
Which drug is contraindicated for pregnant patients with hyperlipidemia? atorvastatin (Lipitor) omega-3 (Lovaza) niacin (Niaspan) colesevelam (Welchol)
atorvastatin (Lipitor)
88
Which drug is considered a cholesterol absorption inhibitor for HLP? atorvastatin (Lipitor) icosapent ethyl (Vascepa) lomitapide mesylate (Juxtapid) ezetimbe (Zetia)
ezetimbe (Zetia)
89
Which of the following is not a contraindication for the drug fenofibrate (Tricor)? Hepatic dysfunction Primary biliary cirrhosis History of myocardial infarction Gallbladder disease
History of myocardial infarction
90
Congenital disorders
Mostly surgical repair for all Tetralogy of Fallot Pulmonary atresia Hypoplastic left heart syndrome Transposition of great vessels
91
Prostaglandin E1 threrapy
Relaxes arterial smooth muscle, producing vasodilation Helps keep Ductus open If ductus is large PGE1 can be started at low dose of 0.01mcg/kg per min
92
Alprostadil
``` Prostaglandin E1 (PDE1) Keep ductus arteriosus open ``` Warning apnea, only use if ventilator is readily available not recommended in respiratory distress syndrome Adverse Apnea, Hypotension, tachycardia, necrotizing enterocolitis, Deterioration, Transfer (apnea)
93
Tetralogy of Fallot (TOF) | 4 components
VSD Overriding aorta Pulmonary (RV) outflow tract obstruction RVH
94
Management of TOF
Severe RVOT obstruction – Neonates with severe RVOT obstruction may require intravenous prostaglandin therapy (alprostadil), ductal stenting, or palliative shunt placement to maintain adequate pulmonary blood flow pending surgical repair. Heart failure symptoms – Patients with minimal obstruction and increased pulmonary blood flow may develop symptoms of heart failure and require pharmacologic treatment (loop diuretic therapy and digoxin). NO ACE or ARB
95
Indomethacin
Indocin Closes ductus Adverse Renal failure, electrolyte imbalance, GI bleed MOA NSAID Accelerates maturation of germinal matrix microvasculature Closes PDA by inhibiting COX enzyme that catalyzes prostaglandin precursor formation from arachidonic acid (70% of patients)
96
Acute infective endocarditis bug
Staph aureus and staph epidermis
97
Subacute infective endocarditis bug
Strep viridans
98
Infective endocarditis Duke criteria Major
Positive blood cultures of S.Aureus, Strep viridans, Strep gallolyticus, HACEK, community acquired enterococcus Persistently positive blood culture New valvular regurgitation murmur Coxiella burneti infection Echo positive for vegetation
99
Prosthetic valve endocarditis Treatment
Synergistic interaction of a cell wall active agent (penicillin, ampicillin, or vancomycin) and an aminoglycoside (gentamicin or streptomycin) if possible
100
Prevention of endocarditis prior to dental or respiratory procedure Med/Dose Oral Amoxicillin
Oral Amoxicillin 2G PO
101
Prevention of endocarditis prior to dental or respiratory procedure Med/Dose Unable to take oral meds Ampicillin
Unable to take oral meds Ampicillin 2G IM/IV
102
Prevention of endocarditis prior to dental or respiratory procedure Med/Dose Unable to take oral meds Ceftriaxone/cefazolin
Unable to take oral meds Ceftriaxone/cefazolin 1 Gm IM/IV
103
Prevention of endocarditis prior to dental or respiratory procedure Med/Dose Allergic to penicillin Cephalexin
Allergic to penicillin Cephalexin 2gm PO
104
Prevention of endocarditis prior to dental or respiratory procedure Med/Dose Allergic to penicillin Clindamycin
Allergic to penicillin Clindamycin 600mg PO
105
Prevention of endocarditis prior to dental or respiratory procedure Med/Dose Allergic to penicillin Azithromycin/clarithromycin
Allergic to penicillin Azithromycin/clarithromycin 500mg PO
106
Prevention of endocarditis prior to dental or respiratory procedure Med/Dose Allergic to penicillin And unable to take oral medication Cefazolin/Ceftriaxone
Allergic to penicillin And unable to take oral medication Cefazolin/Ceftriaxone 1 G IM/IV
107
Prevention of endocarditis prior to dental or respiratory procedure Med/Dose Allergic to penicillin And unable to take oral medication Clindamycin
Allergic to penicillin And unable to take oral medication Clindamycin 600 mg IM/IV
108
Prevention of endocarditis prior to dental or respiratory procedure Med/Dose Allergic to penicillin And unable to take oral medication Vancomycin
``` Allergic to penicillin And unable to take oral medication Vancomycin 15-20 mg/kg IV 2g max ```
109
Acute pericarditis tx
In cases of pericarditis due to an identifiable cause (eg, bacterial infection or malignancy), management is focused upon the underlying disorder and, if necessary, drainage of an associated pericardial effusion. For nearly all patients with acute idiopathic or viral pericarditis, we recommend combination therapy with colchicine plus nonsteroidal anti-inflammatory drugs (NSAIDs) rather than NSAIDs alone. Ibuprofen or ASA + Colchicine If glucocorticoid is needed we suggest the use of moderate initial dosing (eg, 0.2 to 0.5 mg/kg/day of prednisone) followed by a slow taper
110
Colchicine
Recurrent pericarditis 0.6mg PO BID-TID Contra Renal/hepatic impairment with use of CYP3A or P-glycoprotein inhibitors Adverse GI upset, abdominal pain
111
Pericardial effusion
US guided Pericardiocentesis If reappears, repeat pericardiocentesis
112
Aortic aneurysm
for asymptomatic control HTN with BB Can use ACE/ARB if BB not tolerated Can also add statin to help reduce aortic expansion
113
Arterial embolism/thrombosis
For those who present with acute limb ischemia, anticoagulation typically with a heparin (bolus followed by infusion) and intravenous fluid therapy should be immediately initiated prior to making plans for intervention.
114
Arterial embolism/thrombosis | with afib
Patients with ongoing atrial fibrillation and a prior embolic event are at a significantly increased risk of stroke or other embolic event and often warrant lifelong anticoagulation unless there is some other compelling factor. For patients with coronary heart disease equivalents, treatment with aspirin and statins should be a component of their medical therapy.
115
Giant cell arteritis (GCA)
Glucocorticoid treatment is central to the management of giant cell arteritis (GCA, also known as Horton disease, cranial arteritis, and temporal arteritis). If vision is intact at the time appropriate glucocorticoid treatment is initiated, the risk of sight loss is reduced to less than 1 percent. Treatment should be initiated promptly once the diagnosis is confirmed or there is a high index of suspicion for GCA. For patients without visual loss at presentation: prednisone 1 mg/kg or equivalent, not to exceed 60 mg, given in a single daily dose IF GCA relapses add tocilizumab
116
tocilizumab (Actemra)
Giant cell arteritis (Interleukin 6 antagonist) in combination with steroids Warning Serious risk of infection Interactions Avoid live vaccines
117
Peripheral artery disease PAD
Claudication is associated with an increased risk of coronary, cerebrovascular, and renovascular disease, and peripheral artery disease (PAD) is considered to be a coronary heart disease risk equivalent. To reduce the risk for cardiovascular disease progression and complications, we recommend a secondary prevention strategy that includes antiplatelet therapy (aspirin 75 to 162 mg/day or clopidogrel 75 mg/day), smoking cessation, control of blood sugar and blood pressure, lipid-lowering therapy, and dietary modification (as needed) to achieve the goals set in national guidelines. For most patients with lifestyle-limiting claudication who do not have an improvement in symptoms with risk modification and exercise therapy, we suggest a therapeutic trial of naftidrofuryl
118
Cilostazol
Pletal (PDE-3 inhibitor) for intermittent claudication Contra HF Warning HF, Tachycardia, palpitation, tachyarrhythmia, hypotension, exacerbating angina or MI inpatients with ischemic heart disease Interactions CYP3A inhibitors Adverse HA, GI, diarrhea, abdominal pain MOA PDE 3 inhibitor, prevents cAMP degradation which prevents platelet aggregation and promotes vasodilation
119
Venous thrombosis
Anticoagulation administered immediately and for up to 10 days following a diagnosis of DVT to provide protection from recurrent thrombosis in this period of highest risk. Long-term (finite) anticoagulation is administered for a minimum of three months and extended for 6 to 12 months in some cases. A small population of patients will require indefinite anticoagulation (LMW) heparin, subcutaneous fondaparinux, the oral factor Xa inhibitors rivaroxaban or apixaban, or unfractionated heparin (UFH). For most patients with a first episode of DVT (provoked and unprovoked, proximal and distal), anticoagulants should be administered for three months 
120
Pregnant with DVT
LMWH (Lovenox) be selected as the initial and long-term anticoagulant
121
Anticoagulation in Cancer
LMWH (lovenox)
122
Anticoagulation in renal disease | Cr clearance <30
Vitamin K dependent antagonist | Warfarin
123
Anticoagulation in CAD
Vitamin K dependent antagonist Warfarin rivoroxaban apixaban edoxaban
124
Anticoagulation in Pregnancy
LMWH (lovenox)
125
Warfarin
Coumarin anticoagulant. Vitamin K antagonist for Venous thrombosis. Pulmonary embolism. Thromboembolic complications from atrial fibrillation and/or cardiac valve replacement. Reduce risk of death, recurrent MIs, and thromboembolic events (eg, stroke, systemic embolization) post-MI. Dose Individualize. ≥18yrs: Initially 2–5mg once daily Warnings Risk of major or fatal bleeding. Monitor INR frequently. History of GI bleed. Hypertension. Cerebrovascular disease. Anemia. Malignancy. Trauma.
126
Dabigatran
Pradaxa (Direct thrombin inhibitor) To reduce risk of stroke and systemic embolism in non-valvular atrial fibrillation (AF). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients treated with parenteral anticoagulant for 5–10 days. To reduce risk of recurrent DVT/PE in patients who have been previously treated. Prophylaxis of DVT/PE after hip replacement surgery. Contra Active bleeding. Mechanical prosthetic heart valve. Warning Premature discontinuation increases the risk of thrombotic events. Spinal/epidural hematoma Adverse Gastritis-like symptoms (eg, GERD, esophagitis, erosive gastritis, gastric hemorrhage, ulcer),
127
Rivaroxaban
Xarelto (Factor Xa inhibitor) To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Treatment of deep vein thrombosis (DVT), Contra Active bleeding Warning Premature discontinuation increases the risk of thrombotic events. Spinal/epidural hematoma Interactions Increased risk of bleeding with concomitant aspirin, clopidogrel, enoxaparin, warfarin, chronic NSAIDs
128
idarucizumab
Praxbind Reversal of the anticoagulant effects of dabigatran in emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding.
129
Venous insuffciency
For patients who are unable to tolerate, are not compliant with, or in whom compression therapy is contraindicated (eg, occlusive arterial disease), we suggest horse chestnut seed extract. A typical dose is 300 mg (standardized to 50 mg of escin) twice daily. Use horse chestnut extract as a dietary supplement for chronic venous insufficiency (when the veins of the lower leg are unable to send blood back toward the heart), hemorrhoids, and swelling after surgery. Preparations made from the tree’s bark are applied to skin sores. side effects, include itching, nausea, gastrointestinal upset, muscle spasm, or headache.